Company attributes
Other attributes
Evox Therapeutics is a biotechnology company developing exosome therapeutics using exosomes, cell-derived vesicles, to deliver small and large molecule therapeutics. The company is headquartered in Oxford, Oxfordshire, United Kingdom and was founded in 2016 by Per Lundin.
The company has a proprietary technology to modify exosomes to target specific organs such as the brain and central nervous system.Evox Therapeutics has built an intellectual property portfolio encompassing key aspects of extracellular vesicle-based nucleic acid and protein delivery technology.
On May 16, 2016 Evox Therapeutics completed their series A funding round with £10m in funding from Oxford Sciences Innovation.
On September 2, 2018 Evox Therapeutics completed their series B funding round with £35m in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures.
On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655k .
On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million.
